Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Ferlay, Hai-rim Shin, F. Bray, D. Forman, C. Mathers, D. Parkin (2010)
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer, 127
R. Wahl, R. Cody, G. Hutchins, E. Mudgett (1991)
Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose.Radiology, 179 3
A. Buck, H. Schirrmeister, T. Mattfeldt, S. Reske (2004)
Biological characterisation of breast cancer by means of PETEuropean Journal of Nuclear Medicine and Molecular Imaging, 31
C. Elston, I. Ellis (1991)
pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐upHistopathology, 19
R. Mazars, L. Spinardi, M. Bencheikh, J. Simony‐Lafontaine, P. Jeanteur, C. Theillet (1992)
p53 mutations occur in aggressive breast cancer.Cancer research, 52 14
A. Buck, H. Schirrmeister, T. Kühn, Changxian Shen, Thomas Kalker, J. Kotzerke, A. Dankerl, G. Glatting, S. Reske, T. Mattfeldt (2002)
FDG uptake in breast cancer: correlation with biological and clinical prognostic parametersEuropean Journal of Nuclear Medicine and Molecular Imaging, 29
K. Scheidhauer, A. Scharl, U. Pietrzyk, R. Wagner, U. Göhring, K. Schomäcker, H. Schicha (1996)
Qualitative [18F]FDG positron emission tomography in primary breast cancer: clinical relevance and practicabilityEuropean Journal of Nuclear Medicine, 23
N. Avril, J. Dose, F. Jänicke, S. Bense, S. Ziegler, C. Laubenbacher, W. Römer, H. Pache, M. Herz, B. Allgayer, W. Nathrath, H. Graeff, M. Schwaiger (1996)
Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 14 6
A. Mavi, T. Çermik, M. Urhan, Halis Puskulcu, S. Basu, J. Yu, H. Zhuang, B. Czerniecki, A. Alavi (2007)
The Effects of Estrogen, Progesterone, and C-erbB-2 Receptor States on 18F-FDG Uptake of Primary Breast Cancer LesionsJournal of Nuclear Medicine, 48
N. Avril, C. Rose, M. Schelling, J. Dose, W. Kuhn, S. Bense, Wolfgang Weber, S. Ziegler, H. Graeff, M. Schwaiger (2000)
Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18 20
N. Avril, M. Schelling, J. Dose, W. Weber, M. Schwaiger (1999)
Utility of PET in Breast Cancer.Clinical positron imaging : official journal of the Institute for Clinical P.E.T, 2 5
Andrew Blevins, M. González, Joshua Davis (2017)
Speaker presentationsInternational Journal of Antimicrobial Agents, 50
L. Adler, J. Crowe, N. Al‐Kaisi, J. Sunshine (1993)
Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET.Radiology, 187 3
P. Heudel, Sébastien Cimarelli, A. Montella, C. Bouteille, T. Mognetti (2010)
Value of PET-FDG in primary breast cancer based on histopathological and immunohistochemical prognostic factorsInternational Journal of Clinical Oncology, 15
C. Genestie, B. Zafrani, B. Asselain, A. Fourquet, S. Rozan, P. Validire, A. Vincent-Salomon, X. Sastre-Garau (1998)
Comparison of the prognostic value of Scarff-Bloom-Richardson and Nottingham histological grades in a series of 825 cases of breast cancer: major importance of the mitotic count as a component of both grading systems.Anticancer research, 18 1B
Y. Şanlı, S. Kuyumcu, Z. Ozkan, Göknur Işık, H. Karanlık, Burcu Guzelbey, C. Turkmen, S. Ozel, E. Yavuz, A. Mudun (2012)
Increased FDG uptake in breast cancer is associated with prognostic factorsAnnals of Nuclear Medicine, 26
HJ Bloom, WW Richardson (1957)
Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 yearsBr J Cancer, 11
J Alsner, M Yilmaz, P Guldberg, LL Hansen, J Overgaard (2000)
Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patientsClin Cancer Res, 6
A.B.G. Kwast, A. Voogd, M. Menke-Pluijmers, Sabine Linn, G. Sonke, L. Kiemeney, S. Siesling (2014)
Prognostic factors for survival in metastatic breast cancer by hormone receptor statusBreast Cancer Research and Treatment, 145
M. Heiden, D. Plas, J. Rathmell, C. Fox, M. Harris, C. Thompson (2001)
Growth Factors Can Influence Cell Growth and Survival through Effects on Glucose MetabolismMolecular and Cellular Biology, 21
J. Osborne, E. Port, M. Gonen, A. Doane, H. Yeung, W. Gerald, J. Cook, S. Larson (2010)
18F-FDG PET of Locally Invasive Breast Cancer and Association of Estrogen Receptor Status with Standardized Uptake Value: Microarray and Immunohistochemical AnalysisJournal of Nuclear Medicine, 51
K. Ryan, A. Phillips, K. Vousden (2001)
Regulation and function of the p53 tumor suppressor protein.Current opinion in cell biology, 13 3
N. Avril, Manuela Menzel, M. Schelling, Wolfgang Weber, F. Nicke, Walter Nathrath, M. Schwaiger (2001)
Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 42 1
B. Vogelstein, D. Lane, A. Levine (2000)
Surfing the p53 networkNature, 408
Norbert Avril, S. Bense, S. Ziegler, Jã rgdose, Wolfgang Weber, C. Laubenbacher, Wolfgang Rã, Fritz Jã¤nickeand, Markus Schwaiger, Nuklearmedizinische Klinik (1997)
Breast imaging with fluorine-18-FDG PET: quantitative image analysis.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 38 8
S. Ueda, H. Tsuda, Hideki Asakawa, T. Shigekawa, K. Fukatsu, N. Kondo, Mikio Yamamoto, Y. Hama, Katsumi Tamura, Jiro Ishida, Y. Abe, H. Mochizuki (2008)
Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer.Japanese journal of clinical oncology, 38 4
F. Bertucci, P. Finetti, D. Birnbaum (2012)
Basal Breast Cancer: A Complex and Deadly Molecular SubtypeCurrent Molecular Medicine, 12
F. Crippa, E. Seregni, R. Agresti, C. Chiesa, C. Pascali, A. Bogni, D. Decise, V. Sanctis, M. Greco, M. Daidone, E. Bombardieri (1998)
Association between [18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observationEuropean Journal of Nuclear Medicine, 25
S. Reske, K. Grillenberger, G. Glatting, M. Port, Martin Hildebrandt, F. Gansauge, H. Beger (1997)
Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 38 9
T. Higashi, N. Tamaki, T. Honda, T. Torizuka, T. Kimura, T. Inokuma, G. Ohshio, R. Hosotani, M. Imamura, J. Konishi (1997)
Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 38 9
H. Bloom, W. Richardson (1957)
Histological Grading and Prognosis in Breast CancerBritish Journal of Cancer, 11
Purpose The objective of this study was to investigate the in both T1 and T2 breast cancer independently; however, p53 relationship between diversity of F-fluorodeoxyglucose in T1 breast cancer. ( F-FDG) uptake of primary tumor in positron emission to- mography (PET) and various clinicopathologic factors in Keywords F-18 Fluorodeoxyglucose Positron emission . . breast cancer of same pathologic T1, T2 stage. tomography Breast neoplasms TNM staging Methods A total of 258 patients with invasive ductal breast cancer were enrolled in this study. All patients underwent F- FDG PET-CT before surgery. Patients were divided into two Introduction groups according to tumor size based on the pathologic T stage, and maximum standardized uptake value (SUVmax) Breast cancer is the most common malignancy among wom- of 2.5, respectively. en, and the second most frequent cancer overall [1]. In patients Results On the univariate analysis, estrogen receptor (ER), with breast cancer, staging of locally advanced cancer allows tumor size, lymphovascular invasion, p53, pathologic N status appropriate treatment options and offers prognostic informa- (pN) and Nottingham tumor grade (NG) were associated with tion. For this purpose, preoperative F-fluorodeoxyglucose high SUVmax in T1 and T2 breast cancer. On the multivariate ( F-FDG) positron emission tomography-computed
Nuclear Medicine and Molecular Imaging – Springer Journals
Published: Mar 23, 2016
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.